



Dear Colleague,

**Re: PSA-Negative progressive prostate cancer**

Occasionally, one sees patients with advanced prostate cancer who progress following a remission on hormone therapy but in the absence of a rising PSA. There is little information on this group of patients and the castrate resistant prostate cancer subgroup of the NCRI Prostate Cancer CSG is considering a collaborative study. To estimate the number of patients who fall into this group, we would be enormously grateful if you were able to complete the attached brief questionnaire.

We apologise for again asking for your help but the prostate CSG aims to improve clinical management and trial options for men with all types of prostate cancer and it is only by collecting and using this information that a trial can be designed which will be both interesting and valuable for UK uro-oncologists

**1. Are you**

Urological Surgeon

Clinical Oncologist

Medical Oncologist

**2. Do you encounter patients with progressive prostate cancer after primary treatment, despite low levels of serum PSA values (< 10 ng/ml)**

Yes                      No

**3. If yes, how many cases per year do you encounter**

**4. Thinking of the last 5 cases you have seen, what was the site of progression ?**

- |   | <u>Number</u> |
|---|---------------|
| a) Recurrent local disease only                 | _____         |
| b) Nodal disease within pelvis / abdomen        | _____         |
| c) Non regional lymph nodes                     | _____         |
| d) Metastatic disease in bones                  | _____         |
| e) Metastatic disease in other viscera eg liver | _____         |

Do you think this group of patients merits a study                      Yes                      No

Comments:

Thank you very much indeed for your help.

With best wishes,

**Dr Alison Birtle                      Dr Stephen Harland**  
*on behalf of NCRI Prostate Cancer Castrate resistant subgroup*

Please return the questionnaire by fax to 01772 522178 ; by email to [Alison.birtle@lthtr.nhs.uk](mailto:Alison.birtle@lthtr.nhs.uk)  
post to: Dr Alison Birtle Honorary Senior Lecturer & Consultant Clinical Oncologist  
Rosemere Cancer Centre, Royal Preston Hospital, Sharoe Green Lane, Preston, Lancs PR2 9HT